+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Hypertension Drug Market by Therapy, Analysis, Type, Distribution - Cumulative Impact of High Inflation - Forecast 2023-2030

  • PDF Icon

    Report

  • 241 Pages
  • May 2023
  • Region: Global
  • 360iResearch™
  • ID: 4904908
UP TO OFF until Jun 30th 2023
The Global Hypertension Drug Market size was estimated at USD 24.75 billion in 2022, USD 26.88 billion in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.71% to reach USD 48.32 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Hypertension Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Hypertension Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:
  • Based on Therapy, the market is studied across Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta Blockers Vasodilators, Calcium Channel Blockers, Diuretics, and Renin Inhibitors. The Beta Blockers Vasodilators is projected to witness significant market share during forecast period.
  • Based on Analysis, the market is studied across Pulmonary Hypertension Drugs and Systemic Hypertension Drugs. The Systemic Hypertension Drugs is projected to witness significant market share during forecast period.
  • Based on Type, the market is studied across Combination Therapy and Mono Therapy. The Mono Therapy is projected to witness significant market share during forecast period.
  • Based on Distribution, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Hypertension Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hypertension Drug Market, including AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:

  1. Market Penetration: Provides comprehensive information on the market offered by the key players
  2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
  5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  1. What is the market size and forecast of the Global Hypertension Drug Market?
  2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hypertension Drug Market during the forecast period?
  3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hypertension Drug Market?
  4. What is the competitive strategic window for opportunities in the Global Hypertension Drug Market?
  5. What are the technology trends and regulatory frameworks in the Global Hypertension Drug Market?
  6. What is the market share of the leading vendors in the Global Hypertension Drug Market?
  7. What modes and strategic moves are considered suitable for entering the Global Hypertension Drug Market?
Frequently Asked Questions about the Global Hypertension Drug Market

What is the estimated value of the Global Hypertension Drug Market?

The Global Hypertension Drug Market was estimated to be valued at $24.75 Billion in 2022.

What is the growth rate of the Global Hypertension Drug Market?

The growth rate of the Global Hypertension Drug Market is 8.7%, with an estimated value of $48.32 Billion by 2030.

What is the forecasted size of the Global Hypertension Drug Market?

The Global Hypertension Drug Market is estimated to be worth $48.32 Billion by 2030.

Who are the key companies in the Global Hypertension Drug Market?

Key companies in the Global Hypertension Drug Market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, F. Hoffmann, La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc. and Lupin Limited.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hypertension Drug Market, by Therapy, 2022 vs 2030
4.3. Hypertension Drug Market, by Analysis, 2022 vs 2030
4.4. Hypertension Drug Market, by Type, 2022 vs 2030
4.5. Hypertension Drug Market, by Distribution, 2022 vs 2030
4.6. Hypertension Drug Market, by Region, 2022 vs 2030
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in awareness related to complications associated with hypertension
5.1.1.2. Increasing prevalence of hypertension coupled with geriatric population
5.1.1.3. Advances in pharmacologic treatment of hypertension
5.1.2. Restraints
5.1.2.1. Unavailability of hypertension drugs in remote areas
5.1.3. Opportunities
5.1.3.1. Growing initiatives by private and government organizations for R&D
5.1.3.2. Increasing focus on development of new drugs
5.1.4. Challenges
5.1.4.1. Increased concern of side-effects of treatment options
5.1.4.2. Rising number of alternate generic drugs
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization
6. Hypertension Drug Market, by Therapy
6.1. Introduction
6.2. Alpha Blockers
6.3. Angiotensin Converting Enzyme Inhibitor
6.4. Angiotensin Receptor Blockers
6.5. Beta Blockers Vasodilators
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors
7. Hypertension Drug Market, by Analysis
7.1. Introduction
7.2. Pulmonary Hypertension Drugs
7.3. Systemic Hypertension Drugs
8. Hypertension Drug Market, by Type
8.1. Introduction
8.2. Combination Therapy
8.3. Mono Therapy
9. Hypertension Drug Market, by Distribution
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Hypertension Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hypertension Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Hypertension Drug Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
14. Company Usability Profiles
14.1. AstraZeneca PLC
14.2. Bayer AG
14.3. Boehringer Ingelheim International GmbH
14.4. Daiichi Sankyo Company, Limited
14.5. F. Hoffmann-La Roche Ltd.
14.6. Gilead Sciences, Inc.
14.7. GlaxoSmithKline PLC
14.8. Johnson & Johnson Services, Inc.
14.9. Lupin Limited
14.10. Merck KGaA
14.11. Novartis AG
14.12. Pfizer Inc.
14.13. Sanofi S.A.
14.14. Sun Pharmaceutical Industries Limited
14.15. Takeda Pharmaceutical Company Limited
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. HYPERTENSION DRUG MARKET RESEARCH PROCESS
FIGURE 2. HYPERTENSION DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
FIGURE 5. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2022 VS 2030 (%)
FIGURE 6. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 7. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
FIGURE 8. HYPERTENSION DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 9. HYPERTENSION DRUG MARKET DYNAMICS
FIGURE 10. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 11. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 12. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 13. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 14. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 15. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 16. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 18. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 19. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. HYPERTENSION DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 5. HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 6. HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2018-2030 (USD BILLION)
TABLE 7. HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 8. HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2018-2030 (USD BILLION)
TABLE 9. HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 10. HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD BILLION)
TABLE 11. HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD BILLION)
TABLE 12. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 13. HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 14. HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 15. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 16. HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD BILLION)
TABLE 17. HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD BILLION)
TABLE 18. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 19. HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD BILLION)
TABLE 20. HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD BILLION)
TABLE 21. HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD BILLION)
TABLE 22. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 23. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 24. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 25. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 26. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 27. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 28. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 29. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 30. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 31. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 32. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 33. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 34. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 35. CANADA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 36. CANADA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 37. CANADA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 38. CANADA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 39. MEXICO HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 40. MEXICO HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 41. MEXICO HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 42. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 43. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 44. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 45. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 46. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 47. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 48. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 49. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 50. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 51. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 52. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 53. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 54. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 55. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 56. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 57. CHINA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 58. CHINA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 59. CHINA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 60. CHINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 61. INDIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 62. INDIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 63. INDIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 64. INDIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 65. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 66. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 67. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 68. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 69. JAPAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 70. JAPAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 71. JAPAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 72. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 73. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 74. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 75. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 76. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 77. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 78. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 79. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 80. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 81. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 82. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 83. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 84. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 85. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 86. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 87. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 88. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 89. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 90. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 91. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 92. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 93. THAILAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 94. THAILAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 95. THAILAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 96. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 97. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 98. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 99. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 100. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 106. DENMARK HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 107. DENMARK HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 108. DENMARK HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 109. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 110. EGYPT HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 111. EGYPT HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 112. EGYPT HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 113. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 114. FINLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 115. FINLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 116. FINLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 117. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 118. FRANCE HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 119. FRANCE HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 120. FRANCE HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 121. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 122. GERMANY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 123. GERMANY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 124. GERMANY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 125. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 126. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 127. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 128. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 129. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 130. ITALY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 131. ITALY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 132. ITALY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 133. ITALY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 134. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 135. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 136. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 137. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 138. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 139. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 140. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 141. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 142. NORWAY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 143. NORWAY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 144. NORWAY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 145. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 146. POLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 147. POLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 148. POLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 149. POLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 150. QATAR HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 151. QATAR HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 152. QATAR HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 153. QATAR HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 154. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 155. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 156. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 157. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 158. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 159. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 160. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 161. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 162. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 163. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 164. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 165. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 166. SPAIN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 167. SPAIN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 168. SPAIN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 169. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 170. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 171. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 172. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 173. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 174. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 175. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 176. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 177. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 178. TURKEY HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 179. TURKEY HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 180. TURKEY HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 181. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 182. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 183. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 184. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 185. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 186. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD BILLION)
TABLE 187. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2030 (USD BILLION)
TABLE 188. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD BILLION)
TABLE 189. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD BILLION)
TABLE 190. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, SCORES, 2022
TABLE 191. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, BUSINESS STRATEGY, 2022
TABLE 192. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, PRODUCT SATISFACTION, 2022
TABLE 193. HYPERTENSION DRUG MARKET RANKING, BY KEY PLAYER, 2022
TABLE 194. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 195. HYPERTENSION DRUG MARKET LICENSE & PRICING

Companies Mentioned

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...